Document |
Document Title |
WO/2023/245091A1 |
Compositions, systems, and methods are described herein for the modulation, and in particular the reduction or inhibition, of expression or activity of MYC in a cell, animal or human subject. Such compositions, systems, and methods are u...
|
WO/2023/242228A1 |
The present invention relates to 4-substituted (1H-benzo[d]imidazol-2-yl)-1H- pyrazole compounds of the formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment or prevention of cancers assoc...
|
WO/2023/244815A1 |
Described herein, in part, are compounds that mediate the degradation of casein kinase 1α (CK1α), and are therefore useful in the treatment of various disorders, such as cancer.
|
WO/2023/244563A1 |
Disclosed herein are aldehyde dehydrogenase (ALDH-2) inhibitor compounds, such as a compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these inhibitor compounds, and uses of these compounds and compositions,...
|
WO/2023/241618A1 |
Disclosed are a series of aminopyrimidine compounds and use thereof, and specifically disclosed are a compound represented by formula (XI), a stereoisomer thereof and a pharmaceutically acceptable salt thereof, and use thereof.
|
WO/2023/244584A1 |
Disclosed herein are aldehyde dehydrogenase (ALDH-2) inhibitor compounds, such as a compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these inhibitor compounds, and uses of these compounds and compositions,...
|
WO/2023/241627A1 |
The disclosure provides for compounds and methods for modulating or inhibiting CDK8/19.
|
WO/2023/243601A1 |
Provided is an azacycloalkyl carbonyl cyclic amine compound that is useful as an active ingredient in a pharmaceutical composition for treating neutrophilic inflammatory diseases. An azacycloalkyl carbonyl cyclic amine compound according...
|
WO/2023/242597A1 |
The present disclosure relates to a novel class of bifunctional molecules that are useful in a targeted or selective degradation of a protein.
|
WO/2023/236927A1 |
A 4-carbonylaminoisoindoline-1,3-dione compound as represented by formula (I), or an optical isomer, pharmaceutically-acceptable salt, solvate (such as hydrate), inclusion compound, racemate, isotopic marker, or nitrogen oxide thereof; a...
|
WO/2023/237012A1 |
Provided are a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof.
|
WO/2023/239227A1 |
The present invention relates to a novel compound that regulates the function and differentiation of the cytoskeleton, which is involved in pulmonary fibrosis, and thus is useful in the preparation of drugs that can treat associated dise...
|
WO/2023/237732A1 |
The invention concerns compounds having antiviral activity, in particular having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising th...
|
WO/2023/236955A1 |
The present invention relates to the technical field of organic electroluminescent materials, and particularly relates to a polysubstituted carbazole derivative and use thereof. The structural formula of the polysubstituted carbazole der...
|
WO/2023/236920A1 |
This disclosure provides compounds of Formula (1), compositions comprising the same, and methods of using the same, including uses in modulating SARM1 and treating various diseases and conditions, e.g., those caused by axonal degeneration.
|
WO/2023/236945A1 |
The present invention provides a pyridazin-3-carboxamide compound of general formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer, raceme, solvate, hydrate, polymorphic form, prodrug, or isotopic variant thereof. ...
|
WO/2023/240038A1 |
This disclosure provides compounds of Formula (I) (e.g., Formula (I-aa) (e.g., Formula (I-aa-1), (I-aa-2), (I-aa-3), (I-aa-4), (I-aa-5), or (I-aa-6)), Formula (I-a) (e.g., Formula (I-a-1), (I-a-2), (I-a-3), (I-a-4), (I-a-5), or (I-a-6)),...
|
WO/2023/240251A1 |
The present disclosure relates to crystalline polymorphs of (R)-1-(1-(isoquinolin-5-ylsulfonyl)piperidin-4-yl)ethan-1-am
ine, salts thereof, pharmaceutical compositions thereof, pharmaceutical compositions comprising crystalline polymorp...
|
WO/2023/237015A1 |
The present invention relates to the field of biological medicines. Disclosed are N-tetrazolyl aryl urea derivatives, a preparation method therefor, and the use thereof. The present invention has recently discovered the N-tetrazolyl aryl...
|
WO/2023/239697A1 |
The present invention relates to MDM2 degraders, their liquid formulations, and methods of use thereof for treating cancer.
|
WO/2023/236926A1 |
A 4-carbonylamino isoindolin-1-one compound represented by formula (I), or an optical isomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate (such as a hydrate) thereof, or an inclusion compound thereof, or a racemat...
|
WO/2023/239629A1 |
This disclosure provides compounds and pharmaceutically acceptable salts thereof that are useful as modulators of targeted ubiquitination. The compounds disclosed herein bind to and degrade one or more cyclin dependent kinases 2 (CDK2).
|
WO/2023/236199A1 |
The present invention relates to a crystal of an N-(benzoyl)-phenylalanine compound and a pharmaceutical composition thereof, and a preparation method therefor and the use thereof. Specifically, the compound is as represented by formula ...
|
WO/2023/239710A1 |
Novel PI3K inhibitors of the general Formula (1) are described along with methods of their preparation and their use in the treatment of diseases associated with the elevation or activation of the PI3K pathway, wherein R1 to R8 are as de...
|
WO/2023/235925A1 |
The present invention provides compounds of Formula (I), which have activity as inhibitors of MERTK. The present invention also provides radio-labelled compounds which may be used in diagnostic and imaging compositions. The present inven...
|
WO/2023/239941A1 |
The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof, and compositions comprising same. Also described are methods of treating the diseases and disorders disclosed ...
|
WO/2023/239945A1 |
Disclosed herein relates to the biological activities and preparation of 5-(2-(4-(4-fluoro-2- methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-
azaspiro[2.4]-heptan-7-ol (Compound A) stable crystalline form (Compound A-Xln); i...
|
WO/2023/237055A1 |
The present disclosure belongs to the technical field of medicines, and relates to the use of a CDK4/6 inhibitor in treatment of dedifferentiated liposarcoma, in particular to the use of a compound of formula (I) in treatment of dediffer...
|
WO/2023/238112A1 |
The present disclosure encompasses solid state forms of Paltusotine, in embodiments crystalline polymorphs of Paltusotine or salts of Paltusotine, particularly Paltusotine monomesylate and Paltusotine hemimesylate, processes for preparat...
|
WO/2023/236820A1 |
An aromatic six-membered ring-fused imidazole derivative, and a preparation method therefor and the use thereof, which belongs to the field of drug synthesis. Specifically, the present invention relates to an aromatic six-membered ring-f...
|
WO/2023/239750A1 |
This invention provides Degron compounds which bind to cereblon which is a component of the E3 ubiquitin ligase. The Degrons provided herein can be used to modulate the activity of cereblon either alone or as covalently linked to a Tail....
|
WO/2023/239729A1 |
The present disclosure is directed to compounds of Formula (I): wherein m, n, Y, R1, R2, R3, R4 and R5 are each as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable s...
|
WO/2023/239634A2 |
The present invention is directed to novel organic compounds demonstrating the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems. The novel compounds include zwitterion moieties...
|
WO/2023/236947A1 |
The present invention provides a pyridazine-3-carboxamide compound of general formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof. The p...
|
WO/2023/237049A1 |
Disclosed herein are novel bifunctional compounds formed by conjugating IRAK4 inhibitor moieties with E3 ligase ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparati...
|
WO/2023/240205A1 |
The present disclosure provides deuterated compounds and their use as T-type calcium channel blockers in the treatment or prevention of various diseases or disorders associated with calcium T channels.
|
WO/2023/237116A1 |
The present invention discloses a protein degrader such as a GSPT1 degrader and use thereof, particularly use in the prevention and/or treatment of diseases.
|
WO/2023/239846A1 |
The present application provides heterocyclic compounds of formula (I) that modulate the activity of the PI3Ka, which are useful in the treatment of various diseases, including cancer.
|
WO/2023/231795A1 |
The present invention relates to the technical field of organic electroluminescent materials, and particularly relates to a heterocyclic compound and the use thereof. The structural formula of the compound is as shown in formula (I). The...
|
WO/2023/235305A2 |
The invention provides novel sulfonyl cyclic derivatives, and compositions and methods of preparation and use thereof, that are useful in treating various diseases and disorders related to TRPML activities such as lysosome storage diseas...
|
WO/2023/232917A1 |
The invention relates to novel compounds having the general formula (Ib) or (Ib'), (Ib) or (Ib') wherein R1, R2, R6, A3, A4, A5, X, Y and W are as described herein, composition including the compounds and methods of using the compounds.
|
WO/2023/232674A1 |
Compounds of Formula (I) wherein the substituents are as defined in claim 1. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of Formula (I) for controlling wee...
|
WO/2023/232133A1 |
The present invention relates to a compound represented by general formula (I) or a stereoisomer, a deuterated form, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or an eutectic thereof, and an intermediate and a...
|
WO/2023/235535A1 |
Provided are compounds useful for the quantitation and/or characterization of glycans and other similar molecules. Such compounds include compounds of formula (la) or (lb) substituted with at least a TEMPO group or analog thereof and a c...
|
WO/2023/233024A1 |
The invention relates to new compounds of the general Formula (I), which are Dipeptidyl peptidase 9 (DPP9) enzyme inhibitors. The present invention further relates to specific compounds based on Formula (I) that binds to an E3 ligase and...
|
WO/2023/231997A1 |
Provided in the present invention are a pyridazine compound represented by formula (II), and a preparation method therefor and the use thereof. Further disclosed in the present invention is the use of the compound of the present inventio...
|
WO/2023/232673A1 |
Compounds of Formula (I) wherein the substituents are as defined in claim 1. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of Formula (I) for controlling wee...
|
WO/2023/230968A1 |
Provided are an SHP2 inhibitor, and a crystal form thereof, a preparation method therefor, and a use thereof. Provided are a crystal form B of a compound as shown in formula (I), a compound as shown in formula (II) and a crystal form A t...
|
WO/2023/235880A1 |
The disclosure provides compounds of Formula (I) and salts thereof for use in medical treatment.
|
WO/2023/234749A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|